FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID July 12, 2023
NEJM Publishes BRUIN Ph 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with CLL/SLL July 12, 2023
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs for Genetic Diseases, AML and MDS July 5, 2023
FDA Grants Full Approval For Blincyto To Treat MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia June 28, 2023
First Patient Dosed in Ph 2 IMpress Trial of Imetelstat in Patients with R/R AML or Higher Risk MDS June 21, 2023
Updated clinical data from Ph 1/2 KOMET-001 trial of ziftomenib in patients with heavily pretreated and co-mutated R/R NPM1-mutant AML announced June 21, 2023
FDA Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in R/R AML June 21, 2023
Update of Ongoing Ph 1 Study of Voruciclib +/- Venetoclax in Patients with AML or B-Cell Malignancies Announced May 31, 2023
VANFLYTA First FLT3 Inhibitor Approved in Japan for Patients with Newly Diagnosed FLT3-ITD Positive AML May 31, 2023
CytoMed Therapeutics Announces Research Collaboration with Cancer Treatment Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology May 18, 2023
European Commission approves Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma May 18, 2023
Coeptis Therapeutics to Acquire Allogeneic Immuno-Oncology NK Platform in Ph 1 Trials from Deverra Therapeutics April 27, 2023
Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned April 27, 2023
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA April 27, 2023
First Patient dosed in FRIDA, a Ph Ib trial with iadademstat in R/R FLT3-mutant AML patients March 31, 2023
